TAO Synergies is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. The company has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. TAO Synergies was founded in 2012 and is based in New York, New York.
